CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

CollPlant (NASDAQ: CLGN) launched BioFlex, a ready-to-print rhCollagen kit for DLP 3D bioprinting, aimed at drug discovery, engineered tissues and organ fabrication.

Rhea-AI Summary

CollPlant (NASDAQ: CLGN) launched BioFlex, a ready-to-print rhCollagen kit for DLP 3D bioprinting, aimed at drug discovery, engineered tissues and organ fabrication.

BioFlex bundles Collink.3D 50 biodegradable polymer with proprietary photoactive agents and formulation guidelines to enable tunable, high-resolution, reproducible bioinks and faster development.

Argus Feb 23 session

-3.22% close to close Open Argus

Details

News Market Reaction – CLGN

In the Feb 23 session, CLGN declined 3.22%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands CollPlant’s rhCollagen platform with a ready-to-print BioFlex kit aimed at...

Analysis

This announcement expands CollPlant’s rhCollagen platform with a ready-to-print BioFlex kit aimed at DLP 3D bioprinting and advanced tissue models. It follows Q3 2025 results that included $2.3M in 9M revenue and a recent $2.0M registered direct offering with additional warrants. Investors may track adoption of BioFlex by biopharma and academic users, the impact on rhCollagen-based collaborations, and future disclosures on cash runway and commercialization progress.

Key Figures

Q3 2025 GAAP revenue: $77k 9M 2025 revenue: $2.3M Cash balance: $8.5M +5 more

Q3 2025 GAAP revenue

$77k

Quarter ended Sept 30, 2025

9M 2025 revenue

$2.3M

First nine months 2025, driven by AbbVie milestone

Cash balance

$8.5M

As of Sept 30, 2025

9M 2025 net loss

$8.3M

Nine months ended Sept 30, 2025

Workforce reduction

25%

Cost-prioritization initiative to extend runway

Registered direct shares

1,600,000 shares

Ordinary shares offered at $1.25 per share

Offering gross proceeds

$2.0M

Registered direct offering announced Feb 5, 2026

Warrants in placement

3,200,000 shares

Series A and B warrants, 1,600,000 each at $1.25 exercise price

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   Aesthetic strategy update

   24h Move

   -11.9%

   Positioning photocurable rhCollagen dermal filler for GLP-1-related volume loss.

2. Feb 05

   Equity offering

   24h Move

   -53.4%

   Registered direct offering with new shares and warrants for gross proceeds of $2.0M.

3. Nov 26

   Q3 2025 earnings

   24h Move

   -0.5%

   Higher revenue, AbbVie milestone, narrowed loss, and workforce reduction to extend runway.

4. Nov 18

   Earnings date notice

   24h Move

   +0.9%

   Announcement of the upcoming Q3 2025 financial results release date.

5. Oct 27

   Distribution expansion

   24h Move

   +2.4%

   New U.S. logistics center to enhance rhCollagen and BioInk distribution in North America.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

digital light processing (dlp), 3d bioprinting, tissue engineering, regenerative medicine, +4 more

8 terms

digital light processing (dlp) technical

"kit designed for Digital Light Processing (DLP) 3D bioprinting applications."

A projection and light-patterning technology that uses thousands of tiny movable mirrors to steer focused light for high-resolution displays, projectors, and certain types of 3D printing or medical curing processes. Investors watch it because the choice of DLP affects product image quality, manufacturing speed, regulatory compliance for medical devices, and unit costs—like choosing a finer stencil or a sharper projector that can make a product work better and sell more easily.

3d bioprinting technical

"applications in 3D bioprinting, tissue engineering, and regenerative medicine"

3D bioprinting is a manufacturing technique that uses printer-like equipment to place living cells and supportive materials layer by layer to create tissues or organ-like structures, similar to building a model one thin slice at a time. It matters to investors because successful bioprinted products could create new medical therapies, reduce lab time and costs, and open markets in drug testing and transplant alternatives, while also carrying long development timelines and regulatory risk.

tissue engineering medical

"supports advanced applications in 3D bioprinting, tissue engineering, and regenerative medicine"

Tissue engineering is the lab-based process of growing or assembling living cells on supportive frameworks and using biochemical cues to create or repair body tissues, like building replacement parts from living materials. For investors, it matters because successful products can create entirely new markets for treating injuries and chronic diseases, but they also carry long development timelines, high manufacturing costs, and regulatory risk that affect potential returns.

regenerative medicine medical

"applications in 3D bioprinting, tissue engineering, and regenerative medicine"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

bioinks technical

"generate customized, high-performance bioinks with tunable mechanical properties"

Bioinks are printable formulations made from living cells mixed with supportive materials that allow 3D printers to build tissue-like structures layer by layer—think of them as cake batter with seeds that can be shaped into living tissue. They matter to investors because they are the core technology enabling applications like lab-grown tissue for drug testing, medical implants, and future organ fabrication, so advances or commercial adoption can drive growth, partnerships, intellectual property value, and regulatory risk/reward.

biodegradable polymer technical

"includes Collink.3D™ 50, a biodegradable polymer component, together with proprietary photoactive agents"

A biodegradable polymer is a plastic-like material designed to be broken down by natural biological processes into simpler, non-toxic substances over a predictable time frame. Investors pay attention because demand, regulations, and product labeling around such materials can change manufacturing costs, open new markets, and affect a company’s environmental risk and reputation—think of it like choosing a compostable paper towel instead of one that never degrades.

photoactive agents technical

"biodegradable polymer component, together with proprietary photoactive agents optimized for high-resolution DLP"

Photoactive agents are substances that change chemically or physically when exposed to specific wavelengths of light, acting like a light-activated switch that triggers a reaction or effect. Investors care because these agents enable products such as light-based medicines, diagnostic tools, and specialty materials; their commercial value depends on factors like clinical trial success, regulatory approval, manufacturing scalability and patent protection, which drive potential revenue and risk.

scaffolds medical

"highly reproducible bioprinting of scaffolds that closely replicate the physical characteristics of native human tissues"

Scaffolds are man-made frameworks, often made from biodegradable or implantable materials, that provide physical support and guide the growth and organization of cells and tissues for medical treatments such as wound repair, implants or engineered organs. They matter to investors because scaffold design affects how well a therapy works, how hard it is to manufacture and get regulatory approval, and therefore the product’s cost, market potential and risk—much like a building’s foundation determines its strength, cost and resale value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance
• BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility

REHOVOT, Israel, Feb. 23, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.

BioFlex is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues and transplantable organs. This ready-to-print system includes Collink.3D™ 50, a biodegradable polymer component, together with proprietary photoactive agents optimized for high-resolution DLP printing.

By following the BioFlex formulation and printing guidelines, users can efficiently generate customized, high-performance bioinks with tunable mechanical properties, enabling precise fabrication of complex, biologically relevant structures.

This integrated solution eliminates the need for extensive component screening and streamlines formulation development, enabling researchers and industry partners to significantly reduce development time while achieving constructs with precisely controlled physical properties, including enhanced tensile strength, elasticity, reduced brittleness, and improved structural integrity.

Designed to serve both academic laboratories and industrial R&D environments, BioFlex supports advanced applications in 3D bioprinting, tissue engineering, and regenerative medicine, facilitating faster translation from  concept to functional tissue constructs.

"We are committed to empowering both biopharma and academic researchers with high-performance 3D bioprinting solutions," said Yehiel Tal, CEO of CollPlant. "BioFlex, our ready-to-use rhCollagen-based bioink kit, significantly streamlines the formulation process while preserving design flexibility. By integrating our standardized recombinant human collagen with biodegradable polymers and photoactive components - supported by expert-developed formulation and printing guidelines - we enable seamless preparation and highly reproducible, high-resolution printing outcomes."

"Like our other Collink.3D™ bioinks, the BioFlex kit provides a state-of-the-art, animal-free alternative to conventional commercial systems, enabling high-resolution, scalable, and highly reproducible bioprinting of scaffolds that closely replicate the physical characteristics of native human tissues and organs. Our platform is purpose-built to streamline product development, accelerate innovation timelines, and ultimately reduce overall development costs," concluded Tal.

Biofabricated constructs produced using BioFlex demonstrate enhanced mechanical performance, consistency, and safety, supporting advanced applications in tissue engineering and regenerative medicine.

For more information, visit www.CollPlant.com or contact CollPlant at info@CollPlant.com.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com. 

 Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives, plans and strategies, including its plans to empower biopharma and academic researchers with high-performance 3D bioprinting solutions, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com

Photo: https://mma.prnewswire.com/media/2918108/CollPlant_BioFlex_Bioink.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-elevates-rhcollagen-3d-bioprinting-portfolio-with-launch-of-ready-to-print-bioflex-302694478.html

SOURCE CollPlant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CollPlant's BioFlex kit and how does it benefit CLGN investors?

BioFlex is a ready-to-print rhCollagen kit designed for high-resolution DLP bioprinting. According to the company, it bundles Collink.3D 50 with photoactive agents and guidelines to accelerate formulation, reproducibility, and development timelines for biopharma and academic partners.

Which 3D printing method is BioFlex optimized for and what does that enable for CLGN products?

BioFlex is optimized for Digital Light Processing (DLP) 3D bioprinting for precise, high-resolution constructs. According to the company, this enables tunable mechanical properties and consistent printing of tissue-mimetic scaffolds for drug discovery and tissue engineering.

What components are included in CollPlant's BioFlex kit (CLGN) and why are they important?

The kit includes Collink.3D 50 biodegradable polymer plus proprietary photoactive agents and formulation guidelines. According to the company, these components reduce screening needs and enable reproducible, tunable bioink performance for advanced tissue constructs.

How does BioFlex address reproducibility and development time for researchers using CLGN materials?

BioFlex standardizes formulation and printing to cut development time and improve reproducibility. According to the company, following provided guidelines eliminates extensive component screening and accelerates translation from concept to functional constructs.

Who are the target customers for CollPlant's BioFlex (CLGN) and what applications does it support?

Target customers are biopharma companies and academic labs working on tissue models and engineered tissues. According to the company, BioFlex supports drug discovery, tissue engineering, and regenerative medicine, including development of transplantable tissue constructs.